ArticleFrontiers in pharmacology2025

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.

Edy Kornelius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.